Mondrian Investment Partners LTD Raises Stake in GSK plc (NYSE:GSK)

Mondrian Investment Partners LTD boosted its stake in shares of GSK plc (NYSE:GSK - Free Report) by 17.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,838,384 shares of the pharmaceutical company's stock after acquiring an additional 874,004 shares during the period. GSK accounts for about 3.6% of Mondrian Investment Partners LTD's portfolio, making the stock its 2nd biggest position. Mondrian Investment Partners LTD owned about 0.28% of GSK worth $205,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. Avantax Advisory Services Inc. lifted its stake in GSK by 5.7% during the fourth quarter. Avantax Advisory Services Inc. now owns 103,653 shares of the pharmaceutical company's stock worth $3,506,000 after purchasing an additional 5,608 shares during the last quarter. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD acquired a new stake in GSK in the fourth quarter valued at about $11,584,000. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new position in GSK in the fourth quarter valued at about $3,971,000. EverSource Wealth Advisors LLC raised its stake in GSK by 83.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,189 shares of the pharmaceutical company's stock worth $142,000 after acquiring an additional 1,902 shares in the last quarter. Finally, Avantax Planning Partners Inc. increased its position in GSK by 10.0% during the 4th quarter. Avantax Planning Partners Inc. now owns 11,736 shares of the pharmaceutical company's stock worth $397,000 after purchasing an additional 1,071 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GSK shares. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. StockNews.com downgraded shares of GSK from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday. They issued a "neutral" rating and a $35.25 price objective on the stock. Eight analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Stock Up 0.8 %

NYSE:GSK traded up $0.28 on Thursday, hitting $35.65. The stock had a trading volume of 895,470 shares, compared to its average volume of 4,622,745. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The business's fifty day moving average is $37.45 and its 200 day moving average is $36.17. The company has a market cap of $73.56 billion, a PE ratio of 22.41, a P/E/G ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.3932 per share. The ex-dividend date was Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.41%. GSK's payout ratio is presently 100.63%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.